The number of individuals worldwide with Alzheimer’s disease is growing at a rapid rate. Therefore, new treatments are urgently needed….

Atuzaginstat, a novel small-molecule bacterial protease lysine gingipain inhibitor, is currently under investigation as a first-in-class treatment to slow or…

A hallmark feature of Alzheimer’s disease (AD) is the aggregation of amyloid-β (Aβ). Although many trials have been conducted aiming…

The Food and Drug Administration (FDA) has granted accelerated approval to aducanumab for the treatment of early Alzheimer’s disease (AD)….

Alzheimer’s disease (AD) is a degenerative condition that affects the brain due to the accumulation of protein aggregates, mainly amyloid…

The detrimental effects of dementia negatively impact many peoples’ lives – with a markedly decreased quality of life and increased…

Alzheimer’s disease (AD) is a progressive disease affecting millions worldwide and is well known for its characteristic symptom of memory…

Alzheimer’s disease (AD) is a progressive brain disorder that causes a degeneration of memory and cognitive skills majorly caused by…